c-Met抑制剂  

Inhibitor of c-Met

作　　者：李雪[1] 崔宇杰[1] 

机构地区：[1]天津医科大学,天津市300203

出　　处：《医学分子生物学杂志》2008年第1期78-81,共4页Journal of Medical Molecular Biology

基　　金：天津市卫生局科技基金(No.07KZ33)~~

摘　　要：编码肝细胞生长因子酪氨酸激酶受体的c-met原癌基因具有控制细胞生长、侵袭和抗凋亡的作用。Met活化失调在肿瘤发生及其获得侵袭性表型中都有重要的作用。c-Met抑制剂可有效抑制肿瘤细胞生长及转移,从而为抗肿瘤治疗提供了新方法。我们综述了针对c-Met信号途径的抗肿瘤药物开发的4种途径:受体/配体拮抗剂;针对TK催化活性的小分子抑制剂;阻断受体与其下游效应因子的相互作用;降低细胞表面c-Met受体数量。The Met oncogene, encoding the RTK for hepatocyte growth factor （ HGF）, controls genetic programs leading to cell growth, invasion and protection from apoptosis. The deregulated activation of Met is crucial not only to the acquisition of tumorigenesis but also to the acquisition of an invasive phenotype. The inhibitors of c-Met have effects on tumor cell growth and metastasis, which provides a new approach to antitumor therapy. We reviewed four strategies for the development of anticancer drugs： antagonism of ligand/receptor interaction, inhibition of TK catalytic activity, blockade of intracellular receptor/effector interactions cell surface. , and reducing of the amount of c-Met on the

关 键 词：c—Met 肿瘤 抑制剂 

分 类 号：R730.5[医药卫生—肿瘤]